TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
TG Therapeutics, Inc. (TG) filed this Current Report on Form 8-K on May 4, 2015, to announce the results of operations for the first quarter ended March 31, 2015. The company is incorporated in Delaware and maintains its principal executive offices in New York, New York.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body of the report. Investors are directed to the press release (Exhibit 99.1) for a comparison of financial results.
Guidance, Outlook, and Management Commentary
Management announced an investor conference call scheduled for Tuesday, May 5, 2015, at 8:30 am EST. During this call, the company intended to provide a brief financial overview of the first quarter and offer a business outlook for the remainder of 2015. No specific guidance figures or risk factors are detailed in this filing text.
Key Facts for Investor Verification
- Verify the specific Q1 2015 financial results (revenue, net loss, cash position) in the attached press release (Exhibit 99.1).
- Review the business outlook and guidance for the remainder of 2015 provided during the May 5, 2015, investor conference call.
- Confirm the company's cash runway and burn rate as disclosed in the full press release.